Midory Thorikay


My work is concentrated on starting and supporting molecular cell biology-related projects for other group members, training master/PhD students, making sure that the lab runs efficiently, maintaining order in the cell lab, placing orders for reagents, and taking care of reagent requests (antibodies, constructs, etc.) from within and outside LUMC. 


Curriculum Vitae:

I obtained my masters degree in Biochemistry from the University of Conception in 1985, Chile.  In 1986 I became a research scientist at Oncogene Science, Inc, a biotech company located in New York. Here I worked on making synthetic genes, including a gene encoding PTHRP. In 1999 worked as a technician at the Ludwig Institute for Cancer Research, Uppsala, Sweden on the molecular biology of transcription factors. In 2000 I started to work as a technician at Netherlands Cancer Institute, Amsterdam in the group of ten Dijke. This group is focussed on the role of TGF-beta family members in human diseases, in 2005 the group moved to the LUMC.


  • ENDOGLIN is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis.

    Liu Z, Lebrin F, Maring JA, van den Driesche S, van der Brink S, van Dinther M, Thorikay M, Martin S, Kobayashi K, Hawinkels LJ, van Meeteren LA, Pardali E, Korving J, Letarte M, Arthur HM, Theuer C, Goumans MJ, Mummery C, ten Dijke P.

    PLoS One. 2014 Jan 28;9(1):e86273.

  • Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting

    van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Stampino CG, Hu-Lowe D, Goumans MJ, ten Dijke P.

    J Biol Chem. 2012 May 25;287(22):18551-61.

  • Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.

    Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, Seehra J, Heldin CH, ten Dijke P, Pietras K.

    J Exp Med. 2010 Jan 18;207(1):85-100.


Collaborate with us

Looking for information on one of our topics, a new place to conduct your research or experienced research to join forces with?  Feel free to contact us.!

Read more